BeyondSpring, Inc.

BYSI

Before the market opened on December 1, 2021, BeyondSpring announced receipt of a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) rejecting the company’s new drug application (NDA) for a treatment regimen to treat chemotherapy-induced neutropenia containing its drug Plinabulin.

Shares of BeyondSpring stock fell more than 50% in pre-market and intraday trading on December 1, 2021.

Lead Plaintiff deadline
class period
to
Case Documents
No documents available. Contact us if you need a case document.